Expansion of the Spatial Analysis Business through the Acquisition of Curio
First written in FY2026-H1. 1 of 2 entries say "Cited as achieved", first in 2026-05-13. Latest entry: 2026-05-13.
0 other companies' latest entry also says "Cited as achieved".
- 2026-05-13Cited as achievedEarnings
「Curio社の空間解析の基本技術と当社グループが培ってきた遺伝子工学技術・遺伝子解析技術とを組み合わせることで、高いシナジー効果を創出してまいります。」
Curio社の買収および空間解析技術の取り込みについて、通期決算の企業結合注記で買収目的と活用方針を実績として引用している。 - FY2026-H1First statedAnnual report
「The Group has also pursued business development aligned with trends in the NGS market, including launching a single-cell analysis instrument in 2017 and starting a contract spatial analysis service in 2023. Curio is a U.S. startup that develops advanced reagents for spatial analysis and provides reagents enabling high-density, high-resolution spatial analysis using its proprietary DNA barcoded beads. By making Curio part of the Group and combining Curio’s core spatial analysis technology with the Group’s accumulated genetic engineering and genetic analysis technologies, we will create significant synergies. Specifically, we will develop general-purpose reagents compatible with various single-cell analysis instruments, develop high-quality products by combining Curio’s products with the Group’s products to differentiate them from competing products, and expand contract spatial analysis services using Curio’s products.」
On 15 January 2025 (U.S. local time), acquired the shares of Curio Bioscience, Inc. and made it a wholly owned subsidiary. The filing first disclosed the theme and set out plans to combine Curio’s DNA barcoded bead technology for high-density, high-resolution spatial analysis with the Group’s genetic engineering and genetic analysis technologies to expand general-purpose reagents, high-quality products and contract spatial analysis services.